Cocrystal pharma discusses therapeutic platform applications and progress with the stock day podcast

Phoenix, arizona--(newsfile corp. - august 3, 2022) - the stock day podcast welcomed cocrystal pharma, inc. (nasdaq: cocp) ("the company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including sars-cov-2), hepatitis c viruses and noroviruses. cfo and co-interim ceo james (jim) martin joined stock day host sever copley. copley began the interview by asking about the company's platform and influenza therapies.
COCP Ratings Summary
COCP Quant Ranking